

K093621

510(k) Summary
as required by 21 CFR Part 807.87(h)

FEB 28 2010

Identification of the Submitter

Submitter: M. Alaine Medio, RAC
PET and PCS Regulatory Projects Manager
Siemens Medical Solutions USA, Inc.
Molecular Imaging
810 Innovation Drive
Knoxville, TN 37932

Telephone Number: (865)218-2703

Fax Number: (865)218-3019

Name / Address of
Manufacturer Siemens Medical Solutions USA, Inc
Molecular Imaging
2501 N. Barrington Road
Hoffman Estates, IL 60192
USA

Date of Submission: November 20, 2009

Identification of the product

Device Proprietary Name: syngo.PET&CT Oncology

Common Name: Image Processing Software

Classification Name: Picture Archiving and Communication System per 21
CFR 892.2050

Product Code: LLZ

Classification Panel: Radiology

Device Class: Class II

Marketed Devices to which Equivalence is claimed

<u>Device</u>	<u>Manufacturer</u>	<u>510(k) Number</u>
syngo.x (syngo.via)	Siemens AG, Medical Solutions	K092519
True D	Siemens Medical Solutions USA, Inc	K091373
Syngo Dual Energy	Siemens Medical Solutions USA, Inc.	K073003
syngoCT Oncology	Siemens Medical Solutions USA, Inc.	K071310

Device Description:

The syngo.PET&CT Oncology package is a software only medical device which will be delivered on CD-ROM / DVD to be installed onto the commercially available Siemens syngo.via software platform by trained service personnel.

syngo.PET&CT Oncology is a medical diagnostic application for viewing, manipulation, 3D-visualization and comparison of medical images from multiple imaging modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR. The images can be viewed in a number of output formats including MIP and volume rendering.

syngo.PET&CT Oncology enables visualization of information that would otherwise have to be visually compared disjointedly. syngo.PET&CT Oncology provides analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations.

syngo.PET&CT Oncology is designed to support the oncological workflow including interpretation and evaluation of examinations, and follow up documentation of findings.

The syngo.PET&CT Oncology package is similar to the commercially available TrueD software (K091373), syngoCT Oncology (K071310) and syngo Dual Energy software (K073003) in functionality and usage. syngo.PET&CT Oncology is intended to be run on the Siemens syngo.via software platform (K092519) either alone or with other advanced commercially cleared applications.

Safety and Effectiveness:

The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of the device.

Risk Management is ensured via a risk analysis in compliance with ISO 14971:2007 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product. Siemens Medical Solutions, USA Inc. adheres to recognized and established industry standards for development.

Indications for Use:

syngo.PET&CT Oncology is a medical diagnostic application for viewing, manipulation, 3D-visualization and comparison of medical images from multiple imaging modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR.

syngo.PET&CT Oncology enables visualization of information that would otherwise have to be visually compared disjointedly. syngo.PET&CT Oncology provides analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations.

syngo.PET&CT Oncology is designed to support the oncological workflow including interpretation and evaluation of examinations, and follow up documentation of findings.

Note: The clinician retains the ultimate responsibility for making the pertinent diagnosis based on their standard practices and visual comparison of the separate unregistered images. syngo.PET&CT Oncology is a complement to these standard procedures.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room – WO66-G609
Silver Spring, MD 20993-0002

FEB 23 2010

Ms. Alaine Medio, RAC
PET and PCS Regulatory Projects Manager
Siemens Medical Solutions USA, Inc.
810 Innovation Drive
KNOXVILLE TN 37932-2751

Re: K093621

Trade/Device Name: *syngo*.PET&CT Oncology
Regulation Number: 21 CFR 892.2050
Regulation Name: Picture archiving and communications system
Regulatory Class: II
Product Code: LLZ
Dated: November 20, 2009
Received: November 23, 2009

Dear Ms. Medio:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Donald J. St. Pierre
Acting Director
Division of Radiological Devices
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number (if known):

K 093621

Device Name: syngo.PET&CT Oncology

Indications for Use:

syngo.PET&CT Oncology is a medical diagnostic application for viewing, manipulation, 3D-visualization and comparison of medical images from multiple imaging modalities and/or multiple time-points. The application supports functional data, such as PET or SPECT as well as anatomical datasets, such as CT or MR.

syngo.PET&CT Oncology enables visualization of information that would otherwise have to be visually compared disjointedly. syngo.PET&CT Oncology provides analytical tools to help the user assess, and document changes in morphological or functional activity at diagnostic and therapy follow-up examinations.

syngo.PET&CT Oncology is designed to support the oncological workflow including interpretation and evaluation of examinations, and follow up documentation of findings.

Note: The clinician retains the ultimate responsibility for making the pertinent diagnosis based on their standard practices and visual comparison of the separate unregistered images. syngo.PET&CT Oncology is a complement to these standard procedures.

Prescription Use X
(Part 21 CFR 801 Subpart D)


OR

Over the Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)



Concurrence of CDRH, Office of Device Evaluation (ODE)
OVD



(Division Sign-Off)

Division of Radiological Devices

Office of *In Vitro* Diagnostic Device Evaluation and Safety

Page 1 of 1

510(k) Number

K 093621